This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G et al. Intratumoral T cells, recurrence, and survival in epithelian ovarian cancer. N Engl J Med 2003; 348: 203–223.
Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351: 2159–2169.
Dhodapkar MV, Krasovsky J, Osman K, Geller MD . Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J Exp Med 2003; 198: 1753–1757.
Dhodapkar MV . Harnessing host immune responses to preneoplasia: promise and challenges. Cancer Immunol Immunother 2005; 54: 409–413.
Spisek R, Kukreja A, Chen LC, Matthews P, Mazumder A, Vesole D et al. Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J Exp Med 2007; 204: 831–840.
Girardi AJ, Reppucci P, Dierlam P, Rutala W, Coggin Jr JH . Prevention of simian virus 40 tumors by hamster fetal tissue: influence of parity status of donor females on immunogenicity of fetal tissue and on immune cell cytotoxicity. Proc Natl Acad Sci USA 1973; 70: 183–186.
Coggin Jr JH, Ambrose KR, Anderson NG . Phase specific surface autoantigens on membranes of fetus and tumors. Adv Exp Med Biol 1973; 29: 483–490.
Coggin Jr JH, Barsoum AL, Rohrer JW, Thurnher M, Zeis M . Contemporary definitions of tumor specific antigens, immunogens and markers as related to the adaptive responses of the cancer-bearing host. Anticancer Res 2005; 25: 2345–2355.
Siegel S, Wagner A, Friedrichs B, Wendeler A, Wendel L, Kabelitz D et al. Identification of HLA-A*0201-presented T cell epitopes derived from the oncofetal antigen-immature laminin receptor protein in patients with hematological malignancies. J Immunol 2003; 176: 6935–6944.
Siegel S, Wagner A, Kabelitz D, Marget M, Coggin J, Barsoum A et al. Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies. Lymphocytes against hematologic neoplasms by survivin RNA-transfected dendritic cells. Blood 2003; 102: 4416–4423.
Rohrer JW, Barsoum AL, Coggin Jr JH . Identification of oncofetal antigen/immature laminin receptor protein epitopes that activate BALB/c mouse OFA/iLRP-specific effector and regulatory T cell clones. J Immunol 2006; 176: 2844–2856.
Acknowledgements
This work was supported by part of the DFG ZE 697/2-1 grant.
Author information
Authors and Affiliations
Corresponding author
Additional information
The authors declare no financial conflict of interest.
Rights and permissions
About this article
Cite this article
Siegel, S., Friedrichs, B., Budde, AK. et al. In-vivo detectable antibodies directed against the oncofetal antigen/immature laminin receptor can recognize and control myeloma cells—clinical implications. Leukemia 22, 2115–2118 (2008). https://doi.org/10.1038/leu.2008.92
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2008.92